- Conditions
- Systemic Lupus Erythematosus, SLE
- Interventions
- Mycophenolate Mofetil, Hydroxychloroquine or Chloroquine, Prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 227
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- End-Stage Renal Disease
- Interventions
- Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 20 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
- Conditions
- Glioblastoma
- Interventions
- INO-5401, INO-9012, Cemiplimab, Radiation Therapy, Temozolomide
- Biological · Radiation · Drug
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 21
- States / cities
- Duarte, California • Palo Alto, California • San Francisco, California + 15 more
- Conditions
- Melanoma
- Interventions
- ZK-EPO
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
- Interventions
- S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm), Fluorouracil/cisplatin (control arm)
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Alexandria, Louisiana • Albuquerque, New Mexico • Dallas, Texas + 1 more
- Conditions
- Prader-Willi Syndrome
- Interventions
- Setmelanotide, Placebo
- Drug
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Irvine, California • Gainesville, Florida • Kansas City, Kansas + 2 more
- Conditions
- Posttraumatic Osteoarthritis, Anterior Cruciate Ligament (ACL) Rupture
- Interventions
- Synovial Fluid withdrawal at the preoperative clinic visit, Platelet-Rich Plasma (PRP) preparation and injection, Synovial fluid withdrawal at the time of surgery, 3mL synovial fluid withdrawn at the preoperative visit
- Procedure
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Colorectal Adenocarcinoma Metastatic in the Liver
- Interventions
- Pembrolizumab, Odetiglucan
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer Stage IV
- Interventions
- Antroquinonol
- Drug
- Lead sponsor
- Golden Biotechnology Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • San Francisco, California • Chicago, Illinois + 4 more
- Conditions
- Alcohol Withdrawal Delirium
- Interventions
- Baclofen, Placebo, Lorazepam
- Drug
- Lead sponsor
- Essentia Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Duluth, Minnesota
- Conditions
- Pain
- Interventions
- 12 mL paracervical block, 20 mL paracervical block
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Opioid-Use Disorder
- Interventions
- Placebo, TRV734, Oxycodone
- Other · Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer, Brain Metastases, HER2-positive Breast Cancer, CNS Disease
- Interventions
- Tucatinib, Pembrolizumab, Trastuzumab
- Drug
- Lead sponsor
- Reva Basho
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Bevacizumab and Erlotinib
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer
- Interventions
- Pertuzumab, Trastuzumab, Aromatase Inhibitor, Induction Chemotherapy
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 17 more
- Conditions
- Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer
- Interventions
- Cohort 1: Dose Escalation, Cohort 2: Dose Escalation
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • San Francisco, California • Rochester, Minnesota + 1 more
- Conditions
- Irritable Bowel Syndrome Characterized by Constipation
- Interventions
- Botanical Tincture, Placebo
- Drug · Other
- Lead sponsor
- Stamford Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Stamford, Connecticut
- Conditions
- Tobacco-Related Carcinoma
- Interventions
- Smartphone app-based Intervention, Communication intervention, Survey Administration, Interview, Assessment
- Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Las Cruces, New Mexico • Seattle, Washington
- Conditions
- Postoperative Pain, Hip Arthroscopy
- Interventions
- Preop PENG block, Placebo block, Ropivacaine 0.5% Injectable Solution, Normal Saline
- Procedure · Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Lung Cancer
- Interventions
- Carboplatin, irinotecan hydrochloride
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 7
- States / cities
- Owensboro, Kentucky • Chattanooga, Tennessee • Jackson, Tennessee + 2 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Solid Tumor, Colorectal Cancer
- Interventions
- Magrolimab, Cetuximab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Palo Alto, California • Detroit, Michigan + 5 more
- Conditions
- Tobacco Use Disorder, Smoking Cessation
- Interventions
- Web-based curriculum on tobacco dependence treatment, Tobacco Counseling Role Play, Preceptor Training and Teaching Medical Students, Booster Session
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Stanford, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation, Glioma, Malignant
- Interventions
- Niraparib, Resection/Treatment with Niraparib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts